GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (FRA:K3P) » Definitions » Interest Coverage

Kiadis Pharma NV (FRA:K3P) Interest Coverage : 0 (At Loss) (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Kiadis Pharma NV's Operating Income for the six months ended in Dec. 2020 was €-14.24 Mil. Kiadis Pharma NV's Interest Expense for the six months ended in Dec. 2020 was €-0.91 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Kiadis Pharma NV's Interest Coverage or its related term are showing as below:


FRA:K3P's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 144.99
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Kiadis Pharma NV Interest Coverage Historical Data

The historical data trend for Kiadis Pharma NV's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kiadis Pharma NV Interest Coverage Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Interest Coverage
Get a 7-Day Free Trial Premium Member Only - - - - -

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiadis Pharma NV's Interest Coverage

For the Biotechnology subindustry, Kiadis Pharma NV's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Interest Coverage falls into.



Kiadis Pharma NV Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kiadis Pharma NV's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, Kiadis Pharma NV's Interest Expense was €-2.04 Mil. Its Operating Income was €-34.11 Mil. And its Long-Term Debt & Capital Lease Obligation was €5.37 Mil.

Kiadis Pharma NV did not have earnings to cover the interest expense.

Kiadis Pharma NV's Interest Coverage for the quarter that ended in Dec. 2020 is calculated as

Here, for the six months ended in Dec. 2020, Kiadis Pharma NV's Interest Expense was €-0.91 Mil. Its Operating Income was €-14.24 Mil. And its Long-Term Debt & Capital Lease Obligation was €5.37 Mil.

Kiadis Pharma NV did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Kiadis Pharma NV  (FRA:K3P) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Kiadis Pharma NV Interest Coverage Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (FRA:K3P) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (FRA:K3P) Headlines

No Headlines